08/09/2024 | Press release | Distributed by Public on 08/09/2024 04:02
TABLE OF CONTENTS
☒
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
Bionano Genomics, Inc.
|
(Name of Registrant as Specified In Its Charter)
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
☒
|
No fee required
|
☐
|
Fee paid previously with preliminary materials
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
TABLE OF CONTENTS
1.
|
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 35,026,272 shares of common stock upon the exercise of certain Series A warrants and Series B warrants issued in connection with a private placement pursuant to the securities purchase agreement dated July 4, 2024, between the Company and certain institutional investors thereto.
|
| |
By Order of the Board of Directors
|
|
| | ||
| |
/s/ Jonathan Dixon
|
|
| |
Jonathan Dixon
Secretary
|
TABLE OF CONTENTS
TABLE OF CONTENTS
Proposals
|
| |
Page
|
| |
Board
Recommendation
|
Proposal 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 35,026,272 shares of common stock upon the exercise of certain Series A Warrants and Series B Warrants (each, as defined below) issued in connection with a private placement pursuant to securities purchase agreement dated July 4, 2024, between the Company and certain institutional investors thereto (the "Purchase Agreement") ("Proposal 1" or the "Share Issuance Proposal").
|
| |
7
|
| |
For
|
TABLE OF CONTENTS
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
|
| |
1
|
PROPOSAL 1: APPROVAL OF COMMON STOCK ISSUANCE UNDERLYING PURCHASE WARRANTS
|
| |
7
|
HOUSEHOLDING OF PROXY MATERIALS
|
| |
12
|
OTHER MATTERS
|
| |
14
|
TABLE OF CONTENTS
•
|
Any stockholder may listen to the Special Meeting via audio webcast at https://www.virtualshareholdermeeting.com/BNGO2024SM. The webcast will begin at 10:00 a.m. Pacific Time.
|
•
|
Stockholders of record as of the Record Date may vote during the Special Meeting via live audio webcast.
|
•
|
To enter the meeting, please enter your control number.
|
•
|
If you do not have your control number, you will be able to listen to the meeting only and you will not be able to vote or submit questions during the meeting.
|
•
|
Instructions on how to connect to and participate in the Special Meeting via the internet are posted at https://www.virtualshareholdermeeting.com/BNGO2024SM.
|
TABLE OF CONTENTS
•
|
Proposal 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 35,026,272 shares of common stock upon exercise of certain Series A Warrants and Series B Warrants issued in connection with a private placement pursuant to the Purchase Agreement.
|
TABLE OF CONTENTS
•
|
VOTE BY INTERNET: To vote through the internet, go to www.proxyvote.com to complete an electronic proxy card. You will be asked to provide the control number from the Notice, on your voting instruction form, on your proxy card or on the instructions that accompanied your proxy materials. Your internet vote must be received by 11:59 p.m., Eastern Time on Tuesday, October 1, 2024 to be counted.
|
•
|
VOTE BY PHONE: To vote over the telephone, dial toll-free 800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice, voting instruction form or proxy card. Your telephone vote must be received by 11:59 p.m., Eastern Time on Tuesday, October 1, 2024 to be counted.
|
•
|
VOTE BY PROXY CARD: To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered to you and return it promptly in the envelope provided. If you return your signed proxy card to us before the Special Meeting, we will vote your shares as you direct.
|
•
|
VOTE DURING MEETING: To vote online during the Special Meeting, follow the provided instructions to join the Special Meeting at https://www.virtualshareholdermeeting.com/BNGO2024SM, starting at 10:00 a.m. Pacific Time on Tuesday, October 2, 2024.
|
TABLE OF CONTENTS
•
|
You may submit another properly completed proxy card with a later date.
|
TABLE OF CONTENTS
•
|
You may grant a subsequent proxy by telephone or through the internet.
|
•
|
You may send a timely written notice that you are revoking your proxy to: Secretary of Bionano Genomics, Inc., 9540 Towne Centre Drive, Suite 100, San Diego, CA 92121.
|
•
|
You may vote during the Special Meeting which will be hosted via the internet. Simply attending the Special Meeting online will not, by itself, revoke your proxy. Even if you plan to attend the Special Meeting online, we recommend that you also submit your proxy or voting instructions or vote by telephone or through the internet so that your vote will be counted if you later decide not to attend the Special Meeting online.
|
Proposal
Number
|
| |
Proposal
Description
|
| |
Vote Required for Approval
|
| |
Voting Options
|
| |
Effect of
Abstentions
|
| |
Effect of
Broker Non-
Votes (if any)
|
| |
Board
Recommendation
|
1
|
| |
Share Issuance Proposal
|
| |
"For" votes from the holders of a majority of total votes cast on the matter
|
| |
FOR, AGAINST,
or ABSTAIN
|
| |
No effect
|
| |
N/A
|
| |
FOR
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
|
•
|
each of our directors;
|
•
|
each of our named executive officers; and
|
•
|
all of our current executive officers and directors as a group.
|
Name of Beneficial Owner
|
| |
Shares
Owned
Directly
|
| |
Securities
Exercisable
within 60
Days of
August 1,
2024
|
| |
Warrants
|
| |
Number of
Shares
Beneficially
Owned(1)
|
| |
%(2)
|
Greater than 5% Stockholders
|
| | | | | | | | | | |||||
Armistice Capital Master Fund Ltd.(3)
|
| |
5,000,000
|
| |
-
|
| |
-
|
| |
5,000,000
|
| |
5.81%
|
Directors and Named Executive Officers
|
| | | | | | | | | | |||||
David L. Barker, Ph.D.
|
| |
5,836
|
| |
58,324
|
| |
-
|
| |
64,160
|
| |
*
|
R. Erik Holmlin, Ph.D.(4)
|
| |
121,966
|
| |
304,260
|
| |
-
|
| |
426,226
|
| |
*
|
Yvonne Linney, Ph.D.
|
| |
-
|
| |
64,308
|
| |
-
|
| |
64,308
|
| |
*
|
Albert Luderer, Ph.D.
|
| |
-
|
| |
62,362
|
| |
-
|
| |
62,362
|
| |
*
|
Hannah Mamuszka
|
| |
6,578
|
| |
66,308
|
| |
-
|
| |
72,886
|
| |
*
|
Aleksandar Rajkovik, M.D., Ph.D.
|
| |
-
|
| |
65,731
|
| |
-
|
| |
65,731
|
| |
*
|
Christopher J. Twomey(5)
|
| |
6,450
|
| |
61,458
|
| |
5,450
|
| |
73,358
|
| |
*
|
Kristiina Vuori, M.D., Ph.D.
|
| |
-
|
| |
61,243
|
| |
-
|
| |
61,243
|
| |
*
|
Vincent Wong, J.D.
|
| |
-
|
| |
60,129
|
| |
-
|
| |
60,129
|
| |
*
|
Alka Chaubey, Ph.D., FACMG
|
| |
43,398
|
| |
138,369
|
| |
-
|
| |
186,767
|
| |
*
|
Mark Oldakowski
|
| |
64,851
|
| |
139,242
|
| |
-
|
| |
204,093
|
| |
*
|
All current executive officers and directors as a group (13 persons)(6)
|
| |
288,104
|
| |
1,143,969
|
| |
5,450
|
| |
1,437,250
|
| |
1.65%
|
*
|
Represents beneficial ownership of less than 1%.
|
(1)
|
Beneficial ownership is determined in accordance with SEC rules. In computing the beneficial ownership we have included shares for which the named person has sole or shared power over voting or investment decisions. The number of shares of common stock beneficially owned includes common stock which the named person has the right to acquire, through option exercise, RSU vesting, warrant exercise or otherwise, within 60 days after August 1, 2024. No other person or group of affiliated persons is known by us to beneficially own more than 5% of our common stock as of August 1, 2024.
|
(2)
|
For each named person, the percentage ownership includes common stock that the person has the right to acquire within 60 days after August 1, 2024, as described in Footnote 1. However, such shares are not deemed outstanding with respect to the calculation of ownership percentage for any other person. In some cases, beneficial ownership calculations for five percent or greater stockholders are based solely on publicly-filed Schedules 13D or 13G, which five percent or greater stockholders are required to file with the SEC, and which generally set forth ownership interests as of August 1, 2024 unless otherwise provided.
|
(3)
|
We have been advised that, as of August 1, 2024, Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund") held 5,000,000 shares of common stock and warrants to purchase 25,810,080 shares of common stock. The warrants held by the Master Fund are subject to a beneficial ownership limitation of 4.99%, which prohibits the Master Fund from exercising any portion of the warrants to the extent that, following such exercise, the Master Fund's ownership of our common stock would exceed the beneficial
|
TABLE OF CONTENTS
(4)
|
The indicated ownership includes 502 shares held indirectly through the Robert Erik Holmlin IRA.
|
(5)
|
The indicated ownership consists of (i) 6,450 shares of common stock held by the Christopher J. Twomey and Rebecca J. Twomey Family Trust U.T.D. September 20, 2002 for which Christopher J. Twomey and Rebecca J. Twomey serve as co-trustees (the "Trust"), (ii) 4,500 warrants to purchase one share of the Company's common stock, expiring on April 6, 2025, held by the Trust and (iii) 950 warrants to purchase one share of the Company's common stock, expiring on October 23, 2024, held by the Trust.
|
(6)
|
Consists of (i) shares identified in the list of directors and executive officers above; (ii) 34,025 shares of common stock held by Jonathan Dixon and Gulsen Kama; and (iii) 61,962 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of August 1, 2024 by Jonathan Dixon and Gulsen Kama.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
| |
By Order of the Board of Directors
|
|
| | ||
| |
/s/ Jonathan Dixon
|
|
| |
Jonathan Dixon
Secretary
|
TABLE OF CONTENTS
TABLE OF CONTENTS